Tea Beverage in Chemoprevention of Prostate Cancer: A Mini-Review

Nutrition and Cancer

Volumn 47, Issue 1, 2003, Pages 13-23

  Saleem, Mohammad ^a   Adhami, Vaqar Mustafa ^a   Siddiqui, Imtiaz Ahmad ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; POLYPHENOL; SOMATOMEDIN C;

ANGIOGENESIS; APOPTOSIS; CANCER PREVENTION; CELL DEATH; DIET SUPPLEMENTATION; HUMAN; PHYTOCHEMISTRY; PROSTATE CANCER; SHORT SURVEY; TEA;

ANIMALIA; MUS MUSCULUS;

EID: 1342344071     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc4701_2     Document Type: Short Survey

References (135)

1. Gronberg H: Prostate cancer epidemiology. Lancet 361, 859-864, 2003.
2. Parkin DM, Bray FI, and Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 37, S4-S66, 2001.
3. Greenlee RT, Murray T, Bolden S, and Wingo PA: Cancer statistics. CA Cancer J Clin 50, 7-33, 2000.
4. Greenlee RT, Hill-Hormon MB, and Murray T: Cancer statistics. CA Cancer J Clin 51, 15-36, 2001.
5. American Cancer Society: Cancer Facts and Figures. (Available at the web site http://cancer.org/downloads/stt/cancer facts and figures 2003 TM.pdf) 2003.
6. Hill P, Garbaczewski L, Helman P, Walker AR, Games H, et al.: Environmental factors and breast and prostatic cancer. Cancer Res 41, 3817-3928, 1981.
7. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, et al.: Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103, 323-328, 2003.
8. Terry PD, Rohan TE, and Wolk A: Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 77, 532-543, 2003.
9. Kristal AR, Cohen JH, Qu P, and Stanford JL: Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11, 719-725, 2002.
10. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, et al.: A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 12, 557-567, 2001.
11. Jani AB and Hellman S: Early prostate cancer: clinical decision-making. Lancet 361, 1045-1053, 2003.
12. Lamson DW and Brignall MS: Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev 6, 167-187, 2001.
13. Giovannucci E and Clinton SK: Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med 218, 129-139, 1998.
14. Stoner GD and Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 22, 169-180, 1995.
15. Wang ZY, Cheng SJ, Zhou ZC, Athar M, Khan WA, et al.: Antimutagenic activity of green tea polyphenols. Mutat Res 223, 273-285, 1989.
16. Gupta S, Ahmad N, Mohan RR, Husain MM, and Mukhtar H: Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of omithine decarboxylase. Cancer Res 59, 2115-2120, 1999.
17. Mukhtar H and Ahmad N: Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol 158, 207-217, 1999.
18. Ren S and Lien EJ: Natural products and their derivatives as cancer chemopreventive agents. Prog Drug Res 48, 147-171, 1997.
19. Kelloff GJ, Lieberman R, and Steele VE: Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 35, 342-350, 1999.
20. Lippman SM, Lee JJ, and Sabichi AL: Cancer chemoprevention: progress and promise. JNCI 90, 1514-1528, 1998.
21. Liberman R: Prostate cancer chemoprevention: strategies for designing efficient clinical trials. Urology 57, 224-229, 2001.
22. Pezzuto JM: Plant-derived anticancer agents. Biochem Pharmacol 53, 121-133, 1997.
23. Ahmad N, Katiyar SK, and Mukhtar H: Cancer chemoprevention by tea polyphenols. In Nutrition and Chemical Toxicity, Ioannides C (ed). West Sussex, UK: John Wiley & Sons, 1998, pp 301-343.
24. Katiyar SK and Mukhtar H: Tea in chemoprevention of cancer: epidemiologic and experimental studies. Int J Oncol 8, 221-238, 1996.
25. Balentine DA, Wiseman SA, and Bouwens LC: The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37, 693-704, 1997.
26. Rechner AR, Wagner E, Van Buren L, Van De Put F, Wiseman S, et al.: Black tea represents a major source of dietary phenolics among regular tea drinkers. Free Radic Res 36, 1127-1135, 2002.
27. Liao S, Kao YH, and Hiipakka RA: Green tea: biochemical and biological basis for health benefits. Vitam Horm 62, 1-94, 2001.
28. Dufresne CJ and Famworth ER: A review of latest research findings on the health promotion properties of tea. J Nutr Biochem 12, 404-421, 2001.
29. Yang CS: Tea and health. Nutrition 15, 946-949, 1999.
30. Muramatsu K, Fukuya M, and Hara Y: Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. J Nutr Sci Vitaminol 32, 613-622, 1986.
31. Kono S, Shinchi K, Wakabayashi K, Honjo S, Todoroki I, et al.: Relation of green tea consumption to serum lipids and lipoproteins in Japanese men. J Epidemiol 16, 128-133, 1996.
32. Fukaya M, Hara Y, and Muramatsu K: Effect of tea leaf catechin (-)-epi-gallocatechin gallate, on plasma cholesterol levels in rats. J Jpn Soc Nutr Food Sci 39, 495-500, 1986.
33. Matsumoto N, Ishigaki F, Ishigki A, Iwashina H, and Hara Y: Reduction of blood glucose levels by tea catechin. BioSci Biotech Biochem 57, 525-527, 1993.
34. Kao Y, Hiipakka RA, and Liao S: Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141, 980-987, 2000.
35. McKay DL and Bulmberg JB: The role of tea in human health: an update. J Am Coll Nutr 21, 1-13, 2002.
36. Yang CS, Maliakal P, and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42, 25-54, 2002.
37. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, and Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. JNCI 89, 1881-1886, 1997.
38. Yang CS and Chung JY: Growth inhibition of human cancer cell lines by tea polyphenols. Curr Pract Med 2, 163-166, 1999.
39. Chan MM, Fong D, Ho CT, and Huang HI: Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. Biochem Pharmacol 54, 1281-1286, 1997.
40. Liang YC, Lin-Shiau SY, Chen CF, and Lin JK: Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem 75, 1-12, 1999.
41. Ahmad N, Adhami VM, Gupta S, Cheng P, and Mukhtar H: Role of the retinoblastoma (pRb)-E2F/DP pathway in cancer chemopreventive effects of green tea polyphenol epigallocatechin-3-gallate. Arch Biochem Biophys 398, 125-131, 2002.
42. Afaq F, Adhami VM, Ahmad N, and Mukhtar H: Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea constituent (-)-epigallocatechin-3-gallate. Oncogene 22, 1035-1044, 2003.
43. Yang GY, Liao J, Kim K, Yurkow EJ, and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19, 611-616, 1998.
44. Chung JY, Huang C, Meng X, Dong Z, and Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 59, 4610-4617, 1999.
45. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, et al.: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19, 1830-1838, 2001.
46. Liao S, Umekita Y, and Guo J: Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 96, 239-243, 1995.
47. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, et al.: Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 5, 143-147, 1999.
48. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, et al.: Metastatic prostate cancer in a transgenic mouse. Cancer Res 56, 4096-4102, 1996.
49. Gupta S, Hastak K, Ahmad N, Lewin JS, and Mukhtar H: Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98, 10350-10355, 2001.
50. Weisburger JH, Nagao M, and Wakabayashi A: Prevention of heterocyclic amine formation by tea and tea polyphenols. Cancer Lett 83, 143-147, 1994.
51. Fleshner NE and Klotz LH: Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metastasis Rev 17, 325-330, 1998.
52. Debruyne F: Hormonal therapy of prostate cancer. Semin Urol Oncol 20, 4-9, 2000.
53. Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941. J Urol 168, 9-12, 2002.
54. Gleave M, Bruchovsky N, Goldenberg SL, and Rennie P: Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 34, 37-41, 1998.
55. Brawley OW, Ford LG, Thompson I, Perlman JA, and Kramer BS: 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3, 177-182, 1994.
56. Tsukamoto S, Akaza H, Imada S, Koiso K, Shirai T, et al.: Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. JNCI 87, 842-843, 1995.
57. Tsukamoto S, Akaza H, Onozawa M, Shirai T, and Ideyama Y: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 82, 531-537, 1998.
58. Brawley OW and Barnes ST: Potential agents for prostate cancer chemoprevention. Epidemiol Rev 23, 168-172, 2001.
59. Liao S and Hiipakka RA: Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 214, 833-838, 1995.
60. Hiipakka RA, Zhang HZ, Dai W, Dai Q, and Liao S: Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 63, 1165-1176, 2002.
61. Koivisto P, Kolmer M, Visakorpi T, and Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152, 1-9, 1998.
62. Koivisto P, Visakorpi T, Rantala I, and Isola J: Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol 183, 51-56, 1997.
63. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, et al.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-406, 1995.
64. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, et al.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332, 1393-1398, 1995.
65. Ren F, Zhang S, Mitchell SH, Butler R, and Young CY: Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 9, 1924-1932, 2000.
66. Takane KK and McPhaul MJ: Functional analysis of the human androgen receptor promoter. Mol Cell Endocrinol 119, 83-93, 1996.
67. Chen S, Supakar PC, Vellanoweth RL, Song CS, Chatterjee B, et al.: Functional role of a conformationally flexible omopurine/homopyrimidine domain of the androgen receptor gene promoter interacting with Sp1 and a pyrimidine single strand DNA-binding protein. Mol Endocrinol 11, 3-15, 1997.
68. Philipsen S and Suske G: A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res 27, 2991-3000, 1999.
69. Gupta S, Ahmad N, Nieminen AL, and Mukhtar H: Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 164, 82-90, 2000.
70. Webber MM, Waghray A, and Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1, 1089-1094, 1995.
71. Grossfeld GD and Carroll PR: Prostate cancer early detection: a clinical perspective. Epidemiol Rev 23, 173-180, 2001.
72. Gupta S, Ahmad N, and Mukhtar H: Prostate cancer chemoprevention by green tea. Semin Urol Oncol 17, 70-76, 1999.
73. Danzin C, Jung MJ, Grove J, and Bey P: Effect of alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues. Life Sci 24, 519-524, 1979.
74. Crozat A, Palvimo JJ, Julkunen M, and Janne OA: Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology 130, 1131-1144, 1992.
75. Ahmad N, Gilliam AC, Katiyar SK, O'Brien TG, and Mukhtar H: A definitive role of ornithine decarboxylase in photocarcinogenesis. Am J Pathol 159, 885-892, 2001.
76. Kadmon D: Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem 16H, 122-127, 1992.
77. Heston WD: Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv 11, 217-238, 1991.
78. Bachrach U and Wang YC: Cancer therapy and prevention by green tea: role of ornithine decarboxylase. Amino Acids 22, 1-13, 2002.
79. Bai G, Kasper S, Matusik RJ, Rennie PS, Moshier JA, et al.: Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl 19, 127-135, 1998.
80. Asadi F, Faraj M, Malakouti S, and Kukreja SC: Effect of parathyroid hormone related protein, and dihydrotestosterone on proliferation and omithine decarboxylase mRNA in human prostate cancer cell lines. Int Urol Nephrol 33, 417-422, 2001.
81. Wang SI and Mukhtar H: Gene expression profile in human prostate LNCaP cancer cells by (-)epigallocatechin-3-gallate. Cancer Lett 182, 43-51, 2002.
82. Livneh E and Fishman DD: Linking protein kinase C to cell cycle control. Eur J Biochem 248, 1-9, 1997.
83. Zhang XQ, Lee MS, Zelivianski S, and Lin MF: Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J Biol Chem 276, 2544-2550, 2001.
84. Maxwell SA and Davis GE: Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proc Natl Acad Sci USA 97, 13009-13014, 2000.
85. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, et al.: Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 83, 2534-2539, 1998.
86. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, et al.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. JNCI 85, 1657-1669, 1993.
87. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, et al.: Role of p53 and NF-kB in epigallocatechin-3-gallate induced apoptosis of LNCaP cells. Oncogene 22, 4851-4859, 2003.
88. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348, 2001.
89. Denmeade SR, Lin XS, and Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28, 251-265, 1996.
90. Tang DG and Porter AT: Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32, 284-293, 1997.
91. Paschka AG, Butler R, and Young CY: Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 130, 1-7, 1998.
92. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, et al.: Induction of apoptosis by green tea catechins in human prostate cancer DU 145 cells. Life Sci 68, 1207-1214, 2001.
93. Huang S, New L, Pan Z, Han J, and Nemerow GR: Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 275, 12266-12272, 2000.
94. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, et al.: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68, 1980.
95. Jankun J, Selman SH, Swiercz R, and Skrzypczak-Jankun E: Why drinking green tea could prevent cancer. Nature 387, 561, 1997.
96. Jung YD and Ellis LM: Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 82, 309-316, 2001.
97. Singh AK, Seth P, Anthony P, Husain MM, Madhavan S, et al.: Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch Biochem Biophys 401, 29-37, 2002.
98. Cao Y and Cao R: Angiogenesis inhibited by drinking tea. Nature 398, 381, 1999.
99. Adhami VM, Ahmad N, and Mukhtar H: Molecular targets for green tea in prostate cancer prevention. J Nutr 133, 1S-8S, 2003.
100. Zhou JR, Yu L, Zhong Y, and Blackburn GL: Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 133, 516-521, 2003.
101. Furstenberger G and Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 3, 298-302, 2002.
102. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. JNCI 92, 1472-1489, 2000.
103. Kaplan PJ, Mohan S, Cohen P, Foster BA, and Greenberg NM: The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59, 2203-2209, 1999.
104. Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7, 215-223, 1995.
105. Hochstrasser M: Ubiquitin-dependent protein degradation. Annu Rev Genet 30, 405-439, 1996.
106. Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat 2, 215-223, 1999.
107. An B, Goldfarb RH, Siman R, and Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5, 1062-1075, 1998.
108. Lopes UG, Erhardt P, Yao R, and Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272, 12893-12896, 1997.
109. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, et al.: Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem 277, 36570-36576, 2002.
110. Nam S, Smith DM, and Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276, 13322-13330, 2001.
111. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, et al.: Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 8, 382-392, 2002.
112. Mercer WE: Checking on the cell cycle. J Cell Biochem Suppl 30-31, 50-54, 1998.
113. Fernandez PL, Hernandez L, Farre X, Campo E, and Cardesa A: Alterations of cell cycle-regulatory genes in prostate cancer. Pathobiology 70, 1-10, 2002.
114. Davis JN and Day ML: The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis. Mol Biotechnol 22, 129-138, 2002.
115. Lee MH and Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58, 1907-1922, 2001.
116. Vermeulen K, Van Bockstaele DR, and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36, 131-149, 2003.
117. Toogood PL: Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 21, 487-498, 2001.
118. Lin JK, Liang YC, and Lin-Shiau SY: Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 58, 911-915, 1999.
119. Gupta S, Hussain T, and Mukhtar H: Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 410, 177-185, 2003.
120. Heilbrun, LK, Nomura A, and Stemmermann GN: Black tea consumption and cancer risk: a prospective study. Br J Cancer 54, 677-683, 1986.
121. Jain MG, Hislop GT, Howe GR, Burch JD, and Ghadirian P: Alcohol and other beverage use and prostate cancer risk among Canadian men. Int J Cancer 78, 707-711, 1998.
122. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, and Boyle P: Tea consumption and cancer risk. Nutr Cancer 17, 27-31, 1992.
123. Slattery ML and West DW: Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control 4, 559-563, 1993.
124. Ellison LF: Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur J Cancer Prev 9, 125-130, 2000.
125. Jatoi A, Ellison N, Burch AP, Sloan AJ, Dakhil RS, et al.: A phase II trail of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97, 1441-1446, 2003.
126. Lamy S, Gingras D, and Beliveau R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 62, 381-385, 2002.
127. Yang CS, Chen L, Lee MJ, et al.: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 7, 351-354, 1998.
128. Yang CS, Lee MJ, and Chen L: Human salivary tea catechin levels and catechin esterase activities: implications in human cancer prevention studies. Cancer Epidemiol Biomarkers Prev 8, 83-89, 1999.
129. He YH and Kies C: Green and black tea consumption by humans: impact on polyphenol concentrations in feces, blood, and urine. Plant Foods Hum Nutr 46, 221-229, 1994.
130. Lambert JD and Yang CS: Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res 523-524, 201-208, 2003.
131. Li N, Chen X, Liao J, Yang G, Wang S, et al.: Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23, 1307-1313, 2002.
132. Khafif A, Schantz SP, Chou TC, Edelstein D, and Sacks PG: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19, 419-424, 1998.
133. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, et al.: New agents for cancer chemoprevention. J Cell Biochem 26, 1-28, 1996.
134. Report of the Chemoprevention Working Group: Prevention of cancer in the next millennium. Cancer Res 59, 4743-4758, 1999.
135. Liang Y, Lu J, and Zhang L: Comparative study of cream in infusions of black tea and green tea [Camellia sinensis (L) O. Kuntze]. Int J Food Sci Technol 37, 627-634, 2002.